Portico hits noninferiority, but safety looks doubtful. Abbott might want to prioritise a different approach.
Data on the company’s pacemaker-neurostimulator combo are probably good enough to permit further development – but first the company wants to hook a partner.
Feasibility trial success could mean a new therapy, but not for a few years yet.
Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
Amarin is plugging a change in ESC guidelines to include Vascepa, but with the product’s regulatory fate undecided how much difference will this make to sales?
A collection of all of Vantage's coverage from the 2019 European Society of Cardiology meeting.
Carmat says its artificial heart is the best such device in existence. But time is short, and so is money.
With decent efficacy and clean safety in the Orion-11 trial, questions now turn to pricing and whether The Medicines Company will be taken out.
An increased risk of bleeding outweighs Brilinta’s benefits in a primary prevention population, but there might be a way forward in a patient subgroup.